Lipid-Lowering Agents - Gabon

Gabon

The Lipid-Lowering Agents market in Gabon is expected to experience significant growth in the coming years.
It is projected that the revenue in this market will reach US$0.30m in 2024.
Furthermore, an annual growth rate of -0.68% is anticipated from 2024 to 2029, leading to a market volume of US$0.29m by 2029.
In comparison to other countries, United States is predicted to generate the highest revenue in the Lipid-Lowering Agents market.
It is estimated that in 2024, the revenue United States will amount to an impressive US$4,461.00m.
Gabon's market for lipid-lowering agents is witnessing a growing demand due to the increasing prevalence of cardiovascular diseases in the country.

Key regions: Europe, Brazil, France, Australia, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The Lipid-Lowering Agents market in Gabon is experiencing significant growth in recent years.

Customer preferences: Gabon has a high prevalence of cardiovascular diseases, which has led to an increased demand for lipid-lowering agents. Patients are becoming more aware of the benefits of early treatment and prevention of these diseases, leading to an increase in demand for these drugs.

Trends in the market: The market for lipid-lowering agents in Gabon is expected to grow at a steady pace due to the increasing prevalence of cardiovascular diseases. Statins are the most commonly prescribed lipid-lowering agents in Gabon, accounting for a significant share of the market. However, there is also a growing demand for other types of lipid-lowering agents, such as fibrates and bile acid sequestrants.

Local special circumstances: Gabon has a high burden of non-communicable diseases, including cardiovascular diseases. The government has taken steps to address this issue by launching campaigns to raise awareness about prevention and early treatment of these diseases. This has led to an increase in demand for lipid-lowering agents in the country.

Underlying macroeconomic factors: Gabon is a middle-income country with a growing economy. The healthcare sector is a priority for the government, and there have been investments in improving healthcare infrastructure and services. The growing economy and investments in healthcare are expected to drive the growth of the lipid-lowering agents market in Gabon.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.